Series B junior participating preferred purchase rights
- Symbol
- No trading symbol declared
- Exchange
- NASDAQ
- Classification
- RIGHT
Quarterly Report · 10-Q
Revelation Biosciences, Inc.
REVBNASDAQEQUITYCurrent
Quarterly Report
Company context
Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention for acute kidney injury (“AKI”), GEM-CKD as a treatment for chronic kidney disease (“CKD”), GEM-PSI as a prevention for post surgical infection (“PSI”), and GEM-PBI as a prevention of infection in severe burn patients requiring hospitalization (“PBI”). The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California.
Current securities
Registered securities in this filing
REVELATION BIOSCIENCES, INC. · 10-Q · Filed 2026-08-06
Common stock, par value $0.001 per share
- Symbol
- REVB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Redeemable warrants, each exercisable for a 1/201,600th share of common stock at an exercise price of $2,318,400.00 per share
- Symbol
- REVBW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
As-filed source
As filedOpen full document ↗